Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
27 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Hyloris Developments from Liège, company number BE0542737368, closed financial year 2025 with a result of € -5.3 million after tax. For that financial year Hyloris Developments recorded revenue of € 5.1 million and equity of € 17.9 million. Compared with financial year 2024, the result moved from € -5.8 million to € -5.3 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.
€ 17.9 million
▲ € 14.7 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5.3 million
▲ 10 % less loss than in 2024
Profit after tax over the fiscal year.
€ 1.6 million
▲ € 1.3 million vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -11.1 million.
People and assets in 2025
12.2
▲ 1.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.4 million
▲ 14% vs 2024
€ 115,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 33,709
▼ 9% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2.4 million
▼ 45% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 265,052
▲ 22% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | € 5,058,073 | |
| Gross margin | € 956,313 | € 959,710 | € 4,093,114 | € 5,455,411 | ▲ 33% |
| Profit after taxes | € -9,643,600 | € -10,851,687 | € -5,849,328 | € -5,286,075 | ▲ € 563,253 |
| Equity | € 19,922,424 | € 9,070,737 | € 3,221,409 | € 17,935,334 | ▲ € 14.7 million |
| Total debts | € 3,253,450 | € 5,702,950 | € 6,865,897 | € 2,666,104 | ▼ 61% |
| Cash | € 6,518,128 | € 374,951 | € 366,243 | € 1,625,296 | ▲ € 1.3 million |
| Retained profit | € -9,643,600 | € -20,495,287 | € -26,344,615 | € -11,135,403 | ▲ € 15.2 million |
| Balance sheet total | € 23,175,874 | € 14,773,687 | € 10,087,306 | € 20,601,438 | ▲ 104% |
| Employees (FTE) | 8.9 | 10.6 | 10.9 | 12.2 | ▲ 1.3 |
Key figures of Hyloris Developments, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Hyloris Developments?
What happened at Hyloris Developments in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 5.3 million. Source: NBB ↗
- Jacobsen Management SRL stepped down as director. NBB
- SVR Management SRL stepped down as director. NBB
- Jacobsen Management SRL became a director. NBB
- SVR Management SRL became a director. NBB
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
In short
From € 9.6 million loss in 2022 to € 5.3 million loss in 2025.
On average € 447,200 of value added per employee in 2025.
Management
The stake of Hyloris Pharmaceuticals comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Hyloris DevelopmentsThe shares are held by Hyloris Pharmaceuticals (100%).
Directors
According to the 2025 annual accounts
Director · represented by Thomas Jacobsen
Also active at: DERMAX, Hyloris, Hyloris Pharmaceuticals
since 2020 · until 2026
Managing director · represented by Van Rompay Stijn
Also active at: DERMAX, Hyloris, Hyloris Pharmaceuticals
since 2020 · until 2026
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3 box 1
4000 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 27 companies are registered at this address.
All companies at this address →EYED PHARMA
€ 10.5 million revenue · 2025
ONCORADIOMICS
€ 2.4 million gross margin · 2025
DERMAX same network
€ 1.6 million revenue · 2025
Hyloris same network
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
+22 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0542.737.368
- VAT number
- BE 0542.737.368
- Registered office
- Boulevard de Patience et Beaujonc 3 bus 1, 4000 Liège
- Names & denominations
- Hyloris Developments
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 5 December 2013
- Peppol
- Active · Active since 21 Oct 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Vervaardiging van geneesmiddelen